Abstract:Engineered nanomaterials (such as graphene oxide, GO) have shown great potential in biomedical applications as therapeutic and imaging agents. However, little is known about their potential transformations in biological settings, which may alter their physicochemical properties and consequently hinder their biomedical applications. Here, we show that GO undergoes a significant physicochemical transformation in two simulated human lung fluids–Gamble’s solution and artificial lysosomal fluid (ALF), as the organic acids (e.g., citrate and acetate) in the lung fluids cause the reduction of GO, which is mainly due to the conversion of epoxy and carbonyl groups to phenolic groups. This biotransformation markedly inhibits the endocytosis of GO by scavenging macrophages. Notably, the alterations that occur in Gamble’s solution enhance the layer-by-layer aggregation of GO, resulting in the precipitation of GO and a reduction in its interaction with cells, whereas the changes that occur in ALF lead to edge-to-edge aggregation of GO, thereby enhancing the adhesion of large sheet-like GO aggregates on the plasma membrane without cellular uptake. The varied interaction mechanisms with macrophages eventually induce different proinflammatory reactions. Experiments conducted in mice corroborated the morphological alterations of GO in a realistic lung microenvironment. Overall, the findings suggest that the biotransformation of nanomaterials may significantly alter their inherent properties and therefore affect their biosafety, such as the clearance of “worn-out” nanomaterials by immune cells, giving rise to potentially long-term side effects at the accumulation sites. Graphene-oxide particles inserted into the body for biomedical applications such as drug delivery or enhanced imaging can form aggregates over time with possible adverse effects on health, and show researchers in China. After the medical objectives have been achieved, the nanoparticles often remain inside the human body, but it is unclear what happens to them after long time periods in a biological environment. Sijin Liu from the Chinese Academy of Sciences in Beijing, Wei Chen from Nankai University in Tianjin, and their colleagues show that graphene-oxide nanoparticles undergo a physicochemical transformation in simulated human lung fluids, aggregating to form larger particles. This reduces their interaction with cells and inhibits cellular uptake, and can induce proinflammatory reactions. The results highlight the need to consider the biosafety of nanomaterials and their potential long-term side effects. GO can undergo significant physicochemical transformation in two simulated lung fluids–Gamble’s solution and artificial lysosomal fluid (ALF), as the organic acids in lung fluids cause reduction of GO. Biotransformation markedly inhibits the endocytosis of GO by scavenging macrophages. Notably, alterations in Gamble’s solution enhance the aggregation of GO in a layer-to-layer manner, resulting in GO precipitation and reduced interaction with cells, whereas changes in ALF lead to edge-to-edge aggregation of GO, enhancing the adhesion of large sheet-like GO aggregates on plasma membrane without cellular uptake.

Surface Oxidation of Graphene Oxide Determines Membrane Damage, Lipid Peroxidation, and Cytotoxicity in Macrophages in a Pulmonary Toxicity Model

Size‐Dependent Pulmonary Impact of Thin Graphene Oxide Sheets in Mice: Toward Safe‐by‐Design

Next-Generation Sequencing Reveals Differential Responses to Acute versus Long-Term Exposures to Graphene Oxide in Human Lung Cells

Role of surface charge and oxidative stress in cytotoxicity and genotoxicity of graphene oxide towards human lung fibroblast cells.

Graphene Oxide and Reduced Graphene Oxide Exhibit Cardiotoxicity Through the Regulation of Lipid Peroxidation, Oxidative Stress, and Mitochondrial Dysfunction

The Biotransformation of Graphene Oxide in Lung Fluids Significantly Alters Its Inherent Properties and Bioactivities Toward Immune Cells

Improved in Vitro and in Vivo Biocompatibility of Graphene Oxide Through Surface Modification: Poly(Acrylic Acid)-Functionalization is Superior to PEGylation.

Proteomic profiling of RAW264.7 macrophage cells exposed to graphene oxide: insights into acute cellular responses

Systematic Assessment of the Toxicity and Potential Mechanism of Graphene Derivatives in Vitro and in Vivo

Biocompatibility of graphene oxide intravenously administrated in mice—effects of dose, size and exposure protocols

Dependence of Graphene Oxide (GO) Toxicity on Oxidation Level, Elemental Composition, and Size

Graphene Oxide (GO) Sub Chronic Toxicity in Liver, Kidney and Spleen: Macroscopic Observation and Histo-biochemical Examination

Cytotoxicity Effect of Graphene Oxide on Human MDA-MB-231 Cells

Graphene-Induced Pore Formation on Cell Membranes

Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1)

Particle Size-Dependent Antibacterial Activity and Murine Cell Cytotoxicity Induced by Graphene Oxide Nanomaterials

In Vitro Toxicity Evaluation of Graphene Oxide on A549 Cells.

Graphene Oxide Disrupted Mitochondrial Homeostasis Through Inducing Intracellular Redox Deviation and Autophagy-Lysosomal Network Dysfunction in SH-SY5Y Cells

Graphene Oxide Induces P62/sqstm-Dependent Apoptosis Through the Impairment of Autophagic Flux and Lysosomal Dysfunction in PC12 Cells.

Cytotoxicity Evaluation of Oxidized Single-Walled Carbon Nanotubes and Graphene Oxide on Human Hepatoma Hepg2 Cells: an Itraq-Coupled 2d Lc-Ms/Ms Proteome Analysis

Surface Coating-Dependent Cytotoxicity And Degradation Of Graphene Derivatives: Towards The Design Of Non-Toxic, Degradable Nano-Graphene